BiVictriX Therapeutics plc, a biotechnology company, engages in the research and experimental development of pharmaceutical products in the United Kingdom. The company develops Bi-Cygni, a proprietary platform that combines the discovery of novel, cancer-selective twin-antigen pairs or fingerprints with bispecific antibody engineering insights to create anti-cancer therapeutics. Its lead program is BVX001, a first-in-class Bi Cygni antibody drug conjugates to treat acute myeloid leukemia. The company also develops BVX002 for treating ovarian and other solid tumors; and BVX003 for bladder and other solid tumors. The company was formerly known as BiVictriX plc and changed its name to BiVictriX Therapeutics plc in August 2021. BiVictriX Therapeutics plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.